Ben Derman

3.6K posts

Ben Derman banner
Ben Derman

Ben Derman

@bdermanmd

Asst Professor at UChicago, interim director myeloma program. I tweet about: Myeloma & MRD. https://t.co/mPeWg1QjCo

Chicago, IL Katılım Haziran 2017
389 Takip Edilen4.5K Takipçiler
Ben Derman retweetledi
Anna Puła
Anna Puła@anjapula·
Happy to present results from one of the projects I worked on during my time at the University of Chicago at #EHA2026 in Stockholm. Grateful for the opportunity—special thanks to Ben Derman for his support and mentorship. @bdermanmd
Anna Puła tweet media
Stockholm, Sweden 🇸🇪 English
0
1
2
350
Ben Derman
Ben Derman@bdermanmd·
I’m well aware - my point is that now we have several approved options that are better. There are still phase 3 designs incorporating Kd, vpd, elo-pd, etc. If you are a patient facing clinical investigator like me, it’s very hard to justify opening these phase 3 trials with crappy control arms. That’s one of the reasons why US representation in these trials is typically quite low.
English
0
0
2
146
Jing Liang 🇺🇦
Jing Liang 🇺🇦@AppleHelix·
@bdermanmd Keep in mind that trial design comparator arms are typically signed off by the FDA. Hind-sight is always 20/20. But teclistamab was no granted full approval in MM (only accelerated approval) until 2 months ago. x.com/AppleHelix/sta…
Jing Liang 🇺🇦@AppleHelix

A very important context here is that Teclistamab only was granted Accelerated Approval in October 2022, and full approval was not until March 2026! Now, is @papa_heme suggesting that comparator arm should change whenever there is an Accelerated Approval for a new drug? What if confirmatory trial for the AA fail?

English
1
0
2
2.3K
Ben Derman
Ben Derman@bdermanmd·
We now have release of SUCCESSOR-2 data! Mezi + weekly Kd vs twice weekly Kd - 85% anti cd38 refractory - mPFS 18 vs 8 months (control arm did the same as MajesTEC-9) My take: 18 months is nothing to scoff at, and compares favorably with KPd data. It still leaves something to be desired compared to other options in the same lines BUT one more time for those in the rafters - we can stop using Kd and VPd as comparator arms now?
Ben Derman tweet media
Ben Derman@bdermanmd

3) SUCCESSOR-2. Mezi-Kd vs. Kd. It's a late breaker so stay tuned for the data. This will be an important study as it will serve as the FIRST randomized study of carfilzomib with an IMiD/CELMoD. This could help to establish an effective regimen for anti-CD38 refractory patients that isn't T-cell redirecting. Elements to pay attention to: - % anti-CD38 exposed/refractory? - PFS / OS

English
6
6
30
15.6K
Ben Derman
Ben Derman@bdermanmd·
@IC50_cent Have results been presented anywhere? Will this lead to fda approval before? VPd is not an fda approved triplet anyhow. Many have been using KPd based on phase 2 data. This at least provides a new comparator option for future trials too.
English
0
0
0
89
Ben Derman
Ben Derman@bdermanmd·
@NotGenentech @mtmdphd As an investigator here in the US, I feel that. But comparator arms need to be better! This is not only on industry, but also the FDA and just the nature of what is approved.
English
0
0
0
35
FormerlyGenentech
FormerlyGenentech@3Lz3Lo3A·
@bdermanmd @mtmdphd I prefer to run my trials ex-USA. Cheaper and faster. Let's see what the bare minimum enrollment in the USA that is needed to get an FDA approval 🤗
English
1
0
2
67
Ben Derman
Ben Derman@bdermanmd·
Excited to welcome everyone to beautiful Chicago for the @ASCO Annual Meeting! I wanted to highlight some of the most intriguing abstracts in myeloma being presented over the weekend. Let's go!
English
1
7
38
3.3K
Ben Derman
Ben Derman@bdermanmd·
@NotGenentech @mtmdphd great point and good catch - did not see in the table 1 but it's there in the subgroup analysis. Clearly a product of poor comparator arm. Does it change interpretation of the results?
English
1
0
0
45
Ben Derman
Ben Derman@bdermanmd·
@NotGenentech @mtmdphd I don't believe breakdown by country/continent has been made publicly available. But perhaps you have seen this elsewhere
English
2
0
1
54
Samer Al Hadidi, MD,MS,FACP
Samer Al Hadidi, MD,MS,FACP@HadidiSamer·
@bdermanmd The numbers of patients are quite small to have any conclusion. Maybe once a dedicated trial is done for this sub-group it may not show any difference in outcomes
English
2
0
2
361
Ben Derman
Ben Derman@bdermanmd·
Updates from the anselamimab presentation: This was a pre-specified subgroup analysis. These curves for the kappa LC subgroup are impressive, and track with symptomatic improvements. Perhaps there is a real signal here. The paper is out now: ascopubs.org/doi/10.1200/JC…
Ben Derman tweet mediaBen Derman tweet media
Ben Derman@bdermanmd

5) Anselamimab in κ light-chain amyloidosis. Remember: Anselamimab is a monoclonal antibody designed to remove amyloid fibrils. The phase 3 study was negative (no difference in mortality in stage 3a/3b amyloid). But a post-hoc analysis shows anselamimab-treated patients with κ iFLC had a 62% reduction in mortality and a 71% reduction in risk for cardiovascular hospitalization. My take: An interesting signal, but far from definitive. These 'amyloid eaters' have disappointed us so far, but the story is not over!

English
2
3
19
2.9K
Ben Derman
Ben Derman@bdermanmd·
Additions from the LINKER-AL2 presentation: Rapid reduction of FLC, VGPR+ rate 100%, CR rate 90%, no progression events (!) and high rates of renal and cardiac responses.
Ben Derman tweet mediaBen Derman tweet mediaBen Derman tweet mediaBen Derman tweet media
Ben Derman@bdermanmd

4) LINKER-AL2: Linvoseltamab in relapsed AL amyloidosis. (Wechalekar, Lee, 7502) BCMA bispecifics are like magic in this population. In 20 pts: ✅ No DLTs or ICANS ✅ CRS/IRR were Grade 1–2, mostly during step-up dosing ✅ heme OR: 100% with 80 mg; 92% with 240 mg ✅ Median time to hemeCR ~3 weeks Small cohort + short follow-up, but the signal is notable: rapid plasma cell clone suppression in a disease where fast iFLC normalization matters.

English
0
5
32
3.7K
Ben Derman
Ben Derman@bdermanmd·
Working on this study was truly a labor of love! Durca-cel is a BCMA-directed CAR T that was manufactured exceedingly quickly, and this phase I study came at a time when we had very limited slot availability for commercial CAR T. While the PFS was ‘only’ 12 months, we were able to get patients with very challenging disease to CAR T. I think this truly changed the trajectory of their entire disease course. IEC-HS was more common with this product, and we learned a great deal about optimal management of this entity. Shoutout to @adamssperling who put so much effort into this study and to Novartis for their collegiality and support. science.org/doi/10.1126/sc…
English
1
9
35
2K
Ben Derman retweetledi
Vumedi Oncology
Vumedi Oncology@VuMediHemOnc·
🧬 Is CAR-T moving beyond relapsed myeloma and into high-risk smoldering disease? In Part 2 of the Miami Myeloma Cross-Country series, Dr. Dickran Kazandjian (@dikokaz) leads a discussion with Drs. Ola Landgren (@DrOlaLandgren), Kenneth Shain, and Benjamin Derman (@bdermanmd) on the potential role of CAR-T in high-risk smoldering myeloma. The panel explores the promise—and challenges—of earlier intervention, including MRD negativity, neurologic toxicity concerns, and whether aggressive treatment can truly alter disease course. 🎥 Watch on Vumedi: tinyurl.com/yn3sau64 🔗 Visit the Miami Myeloma Cross-Country Vumedi Channel to keep up with hot topics in Myeloma: tinyurl.com/yc2bxf3u Featuring experts from @SylvesterCancer / @UMiamiHealth, @MoffittNews, and @UCCancerCenter / @UChicagoMed With thanks to organizations advancing myeloma research and care, including @theMMRF, @IMFmyeloma, @HealthTree, @ASH_hematology, @AmericanCancer, @Myeloma_Society and @ConquerCancerFd #MMSM #CAR_T
English
0
6
8
853
Ben Derman
Ben Derman@bdermanmd·
10) Cyclophosphamide for 'unrestrained' ALC after Cilta-cel? (Tan, 7543) 22 patients had high ALC (>3K) post-cilta-cel and received cyclophosphamide 500 mg IV/PO x1. Delayed neurotox occurred in 4 pts (18%), including 1 case of IEC-cranial nerve palsy and 3 with parkinsonism. Similar outcomes with prophy dex My take: We still need to find alternative strategies for unrestrained ALC, preferably that don't irrevocably damage CAR T-cells. asco.org/abstracts-pres…
English
0
2
11
717
Ben Derman
Ben Derman@bdermanmd·
9) Final analysis of CEPHEUS (Dara-VRd vs VRd in transplant deferred patients) - Usmani 7513 What's new from this data? We now know that 6-year PFS for Dara-VRd is 59%. Median PFS for high-risk: 58 months Median PFS for ISS 3: 66 months These are useful benchmarks as we talk to patients about the benefits of quad vs triplet in frontline therapy for older adults. asco.org/abstracts-pres…
English
1
2
6
763

Keşfet

@IC50_cent @docbraunstein @mtmdphd @ASCO @HadidiSamer @adamssperling @elonmusk @BarackObama